The advent of highly effective disease modifying therapy has transformed the landscape of
multiple sclerosis (MS) care over the last two decades. However, there remains a critical …

Multiple sclerosis (MS) is an autoimmune disorder of the brain and spinal cord that
predominantly affects white matter. MS has a variable clinical presentation and has no …

BACKGROUND Central nervous system Langerhans cell histiocytosis (CNS‐LCH) brain
involvement may include mass lesions and/or a neurodegenerative disease (LCH‐ND) of …

Objective: Natalizumab inhibits the migration of systemic immune cells to the CNS and may
be beneficial in progressive multiple sclerosis (MS). The objective of the study was to …

Identifying a reliable biomarker may accelerate diagnosis of multiple sclerosis (MS) and lead
to early management of the disease. Accumulating evidence suggest that cerebrospinal fluid …

Multiple sclerosis (MS) is an autoimmune disease of unknown cause, in which chronic
inflammation drives multifocal demyelination of axons in both white and gray matter in the …

In patients with multiple sclerosis (MS) intensive efforts are directed at identifying biomarkers
in bodily fluids related to underlying disease mechanisms, disease activity and progression …

Introduction: Multiple Sclerosis (MS) is the most common immune-mediated chronic
neurodegenerative disease of the central nervous system (CNS) affecting young people …

Objective: To investigate CSF biomarkers of neuroinflammation and neurodegeneration in
Huntington disease (HD) gene-expansion carriers compared to controls and to investigate …

As therapeutic options for multiple sclerosis widen, validated biomarkers of clinical disease
activity are urgently needed. Reliable biomarkers would assist in choosing initial therapy …